膦甲酸钠注射液致周身麻木、呼吸困难1例分析

doi:10.19803/j.1672-8629.2021.02.21

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (2): 196-198.
DOI: 10.19803/j.1672-8629.2021.02.21

膦甲酸钠注射液致周身麻木、呼吸困难1例分析

刘洋, 马春华, 梁连春^*

首都医科大学附属北京佑安医院感染综合科,北京 100069

收稿日期:2020-01-06 修回日期:2021-02-26 出版日期:2021-02-15 发布日期:2021-02-26
通讯作者: ^*梁连春,男,主任医师,新发传染病与感染性疾病的发病机制与临床特征的研究。E-mail: llc671215@sohu.com
作者简介:刘洋,女,硕士,主治医师,中医学。

Cace Analysis of General Numbness and Dyspnea Caused by Foscarnet Sodium for Injection

LIU Yang, MA Chunhua, LIANG Lianchun^*

Department of General Infection, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Received:2020-01-06 Revised:2021-02-26 Online:2021-02-15 Published:2021-02-26

摘要/Abstract

摘要： 目的探讨膦甲酸钠导致周身麻木、呼吸困难的机制及相关文献分析。方法我院既往诊治1例肝衰竭合并巨细胞感染患者,在应用膦甲酸钠时出现周身麻木及呼吸困难等症状,通过文献分析,探讨其发生机制,并结合该病例阐述膦甲酸钠相关不良反应概况。结果膦甲酸钠可导致周身麻木、呼吸困难,其机制可能与低钙血症相关。结论膦甲酸钠应用中应严密监测患者情况,及时发现并处理不良反应。

关键词: 膦甲酸钠, 麻木, 药品不良反应

Abstract: Objective To explore the mechanism of foscarnet sodium causing general numbness and dyspnea and to analyze the related literature. Methods A case of liver failure with cytomegalovirus infection was diagnosed and treated in our hospital. The symptoms of numbness and dyspnea occurred during the application of foscarnet sodium. Through literature analysis, the mechanism of the occurrence of foscarnet sodium related adverse reactions was discussed. Results Foscarnet sodium could cause general numbness and dyspnea, which might be related to hypocalcemia. Conclusion During the application of foscarnet sodium, the patients should be closely monitored, and adverse reactions should be found and treated in time.

Key words: foscarnet sodium, numbness, adverse drug reaction

中图分类号:

R969.3

刘洋, 马春华, 梁连春. 膦甲酸钠注射液致周身麻木、呼吸困难1例分析[J]. 中国药物警戒, 2021, 18(2): 196-198.

LIU Yang, MA Chunhua, LIANG Lianchun. Cace Analysis of General Numbness and Dyspnea Caused by Foscarnet Sodium for Injection[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 196-198.

参考文献

[1] Oberg B.Antiviral effects of phosphonoformate(PFA,foscarnetsodium)[J] .Pharmac Ther, 1989, 40(2): 213-216
[2] Wen HY, Song JC.Research overview of clinical combination of foscarnet sodium[J]. Chinese Journal of Infection Control(中国感染控制杂志), 2019, 18(1): 89-92.
[3] Yu J, Zhang MC.Sodium foscarate eye drops for the treatment of epithelial herpes simplex keratitis[J]. International Journal of Ophthalmology(国际眼科杂志), 2012, 12(5): 899-901.
[4] Hu Y, Liu Y, Liu S, et al.Analysis of adverse reactions of sodium foscarnate in Beijing from 2008 to 2014[J].Chinese Journal of Pharmacy(中国药学杂志), 2015, 50(18): 1634-1638.
[5] Li DD, Xie Q, Wang Y, et al.Sodium foscarnate-related acute renal failure[J]. Journal of adverse drug reactions(药物不良反应杂志), 2012, 14(5): 317-319.
[6] Wang P, Peng H, Lou FD, et al.2 cases of hypocalcemia and hypokalemia caused by sodium foscarnate[J].Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2001,21(1):62.
[7] Chen KJ, Li XL, Zhang YC.One case of limb numbness caused by phosphonic acid sodium chloride injection[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2017,26(2):149-150.
[8] Xue XL, Chen YY.Analysis of adverse reactions of sodium foscarnate in AIDS patients in our hospital[J]. Zhongnan Pharmacy(中南药学), 2018, 16(12): 1803-1807.
[9] Zhang X.Clinical study on cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation [D]. Third Military Medical University(第三军医大学), 2017.
[10] Ling YK, Yan ZH, Lin QL, et al.Chinese material medica (中药学)[M]. Shanghai : Shanghai Science and Technology Press, 1999:212-213.
[11] Lan L, Cao QW, Li CJ.Literature review of polyene phosphatidylcholine adverse reactions[J].Chinese Journal of Drug Abuse Prevention and Control(中国药物滥用防治杂志), 2016, 22(5): 304.
[12] Xu L, Qian K, Yang Y, et al.One case of systemic numbness with transient unconscious caused by sodium phosphate and sodium chloride injection[J]. Pharmaceutical and clinical studies(药学与临床研究), 2019, 27(4): 314.
[13] Sean C S. Martindale Drug Dictionary(马丁代尔药物大典) [M]. 37th Edition. Beijing : Chemical Industry Press, 2013:844-845.
[14] Chen Y, Chen G, Jeremy T, et al.Emergency treatment of acute hypocalcemia in adults in the UK[J]. Journal of Trauma and Emergency(创伤与急诊电子杂志), 2017,5(1):45-46.
[15] Ren KF, Fu Y, Wang D, et al.Ganciclovir and foscarnet sodium in the treatment of recurrent genital herpes curative effect observation[J].Chinese Sexual Science(中国性科学), 2019,28(3):139-142.
[16] Sun Q, Li SM, Dai LJ, et al.A retrospective analysis of ganciclovir versus foscarnet sodium in the treatment of adult EB virus infection[J]. Medical Information(医学信息), 2019,32(z1):188.
[17] Chen HY, Teng W.Comparative observation on the efficacy of sodium phosphonoformate and ganciclovir in the treatment of senile herpes zoster[J]. Chinese Medicine(中国医药), 2012, 7(3): 373-374.
[18] He Q, Kong SY, Xu C, et al.Systematic review of efficacy and safety of foscarnet sodium versus ganciclovir in the treatment of HIV-associated cytomegalovirus retinitis[J]. China Journal of Evidence-based Medicine(中国循证医学杂志), 2006, 6(7): 507-513.
[19] Zhao X, Leng ML, Wang P, et al.Investigation on the status quo and countermeasures of drug adverse reaction information collected by drug manufacturers in China from medical institutions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2018, 15(11): 652-657.

膦甲酸钠注射液致周身麻木、呼吸困难1例分析

Cace Analysis of General Numbness and Dyspnea Caused by Foscarnet Sodium for Injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.